Related Experiment Video

Updated: Nov 20, 2025

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

279

Intensifying Neoadjuvant Therapy for Rectal Cancers Towards Watchful Waiting

Deep Chakrabarti1, Naseem Akhtar2, Shiv Rajan3

  • 1Department of Radiation Oncology, King George's Medical University, Lucknow, India.

Annals of Surgical Oncology
|January 22, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

842

Related Experiment Videos

Last Updated: Nov 20, 2025

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

279
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

842

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

Awake Nebulized Indocyanine Green (ICG) for Tracheobronchial Fluorescence: A Safety and Feasibility Study in Minimally Invasive Esophagectomy.

Indian journal of surgical oncology·2026

DARPP-32 is a novel regulator of M2-macrophage polarization: Sustains STAT6 phosphorylation by directly binding and inhibiting tyrosine phosphatase SHP-1.

Oncogene·2025

The contemporary management of prostate cancer.

CA: a cancer journal for clinicians·2025

Hypofractionation/Ultra-hypofractionation for Prostate Cancer Radiotherapy.

Seminars in radiation oncology·2025

Management of Testicular Cancer.

JCO oncology practice·2025

Prevalence and Detection of Novel Thalassemia Variant hemoglobin J in Extensive Tharu Population.

Annals of African medicine·2025

ASO Editorial: Lymph Node Dissection in the Immunotherapy Era: Friend or Foe?

Annals of surgical oncology·2026

Overall and Cause-Specific Late Mortality in Long-Term Survivors of Early Onset Solid Cancer After Surgery: A Population-Based Retrospective Cohort Study.

Annals of surgical oncology·2026

Bright Visualization of Primary and Metastatic Medullary Thyroid Cancer in an Orthotopic Nude Mouse Model Using a Fluorescent Humanized Anti-CEA Antibody for More Accurate Staging and Improved Resection.

Annals of surgical oncology·2026

Patterns of Lymph Node Metastases After Multimodality Therapy in Esophageal Carcinoma Treated with Robot-Assisted Minimally Invasive Esophagectomy (RAMIE).

Annals of surgical oncology·2026

Changes in Outcomes of Hepatic Cytoreduction for Neuroendocrine Liver Metastases over Two Decades: From Major Hepatectomy to Parenchyma-Sparing Approaches.

Annals of surgical oncology·2026

Determinants of Non-Receipt of Guideline-Concordant Treatment in Pancreatic Cancer: A Classification Tree Analysis.

Annals of surgical oncology·2026

Analysis of real-world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma.

Cancer·2026

RETRACTION: USP44 Suppresses Proliferation and Enhances Apoptosis in Colorectal Cancer Cells by Inactivating the Wnt/β-catenin Pathway via Axin1 Deubiquitination.

Cell biology international·2026

First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data.

Expert review of pharmacoeconomics & outcomes research·2026

Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis.

International journal of urology : official journal of the Japanese Urological Association·2026

Patterns of radiological response to procarbazine and CCNU polychemotherapy in patients with oligodendroglioma.

Neuro-oncology advances·2026

Durable Complete Response Following Nivolumab Discontinuation in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma Complicated by Bullous Pemphigoid: A Case Report.

Cureus·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us